Table 2.
Evaluation of the DNA methylation profiles in the promoter regions of the CDKN2A, MLH1, and APC genes and repetitive sequence LINE-1 in construction workers and controls.
| Cp Genomic Sites | Unexposed Workers | Exposed Workers | p Value | FDR c Corrected p Values | ||||
|---|---|---|---|---|---|---|---|---|
| N | Mean ± SD | Median (IQR) | N | Mean ± SD | Median (IQR) | |||
| CDKN2A (%5mC) | ||||||||
| CpG site 1 | 44 | 2.85 ± 1.89 | 2.81 (0–5.75) | 57 | 3.48 ± 2.57 | 2.97 (0−10.06) | 0.48 b | 0.53 |
| CpG site 2 | 44 | 5.11 ± 2.81 | 5.39 (0–10.35) | 57 | 6.56 ± 3.03 | 6.82 (0−13.58) | 0.02 b,* | 0.04 * |
| CpG site 3 | 44 | 2.51 ± 2.31 | 2.50 (0–6.53) | 57 | 3.25 ± 2.57 | 2.81 (0−9.97) | 0.24 b | 0.31 |
| CpG site 4 | 44 | 4.42 ± 1.51 | 4.4 (0–7.58) | 57 | 5.02 ± 2.00 | 5.08 (0−10.01) | 0.11 b | 0.18 |
| CpG site 5 | 44 | 4.12 ± 2.76 | 4.66 (0–9.47) | 57 | 5.33 ± 2.86 | 5.3 (0−11.62) | 0.08 b | 0.14 |
| CpG site 6 | 44 | 1.93 ± 1.84 | 1.97 (0−5.14) | 57 | 2.47 ± 2.29 | 2.15 (0−8.00) | 0.40 b | 0.47 |
| CpG site 7 | 44 | 4.46 ± 2.35 | 4.67 (0−8.87) | 57 | 5.87 ± 2.37 | 5.68 (0−12.22) | 0.005 b,* | 0.02 * |
| All CpG sites combined | 44 | 3.63 ± 2.04 | 3.68 (0−7.47) | 57 | 4.79 ± 2.57 | 4.44 (0−10.73) | 0.05 b,* | |
| MLH1 (%5mC) | ||||||||
| CpG site 1 | 41 | 4.76 ± 1.54 | 4.35 (2.32−8.63) | 56 | 5.20 ± 1.48 | 5.26 (0−8.10) | 0.15 a | 0.22 |
| CpG site 2 | 41 | 3.69 ± 1.29 | 3.62 (0−5.85) | 56 | 3.70 ± 1.29 | 3.64 (0−6.42) | 0.76 b | 0.76 |
| CpG site 3 | 41 | 3.02 ± 1.80 | 3.27 (0−6.25) | 56 | 3.90 ± 1.27 | 4.03 (0−7.25) | 0.02 b,* | 0.04 * |
| CpG site 4 | 41 | 5.29 ± 2.02 | 5.13 (0−9.50) | 56 | 6.18 ± 1.57 | 6.26 (2.53−9.70) | 0.01 a,* | 0.03 * |
| CpG site 5 | 41 | 4.61 ± 1.87 | 4.10 (0−8.34) | 56 | 5.90 ± 1.50 | 5.92 (2.42−9.59) | 0.001 b,* | 0.01 * |
| CpG site 6 | 41 | 1.91 ± 2.01 | 2.06 (0−5.72) | 56 | 3.86 ± 1.47 | 3.95 (0−8.47) | 0.001 b,* | 0.01 * |
| All CpG sites combined | 41 | 4.22 ± 1.55 | 4.00 (1.74−7.49) | 56 | 5.04 ± 1.38 | 5.03 (1.61−9.76) | 0.007 a,* | |
| APC (%5mC) | ||||||||
| CpG site 1 | 47 | 8.78 ± 10.14 | 7.48 (0−68.05) | 58 | 8.08 ± 3.26 | 8.13 (2.59−21.49) | 0.65 b | 0.68 |
| CpG site 2 | 47 | 1.99 ± 2.72 | 0.00 (0−9.46) | 58 | 3.43 ± 2.21 | 3.57 (0−11.01) | 0.002 b,* | 0.01 * |
| CpG site 3 | 47 | 4.22 ± 2.20 | 4.00 (0−12.18) | 58 | 5.13 ± 1.66 | 5.03 (1.61−11.51) | 0.013 b,* | 0.03 * |
| All CpG sites combined | 47 | 5.47 ± 2.43 | 6.13 (1.29−11.54) | 58 | 6.43 ± 3.33 | 5.73 (1.17−15.48) | 0.29 b | |
| CpG Hot | 47 | 3.11 ± 2.10 | 2.61 (0−10.82) | 58 | 4.29 ± 1.83 | 4.29 (0.81−9.61) | <0.001 b,* | |
| LINE-1 (%5mC) | ||||||||
| CpG site 1 | 44 | 74.45 ± 1.36 | 74.72 (70.72−76.94) | 57 | 73.20 ± 5.08 | 73.83 (36.54−73.17) | 0.01 b,* | 0.03 * |
| CpG site 2 | 44 | 73.42 ± 7.30 | 68.87 (66.92−84.14) | 57 | 72.52 ± 7.78 | 67.84 (64.95−85.26) | 0.16 b | 0.22 |
| CpG site 3 | 44 | 63.13 ± 6.68 | 58.82 (55.87−73.13) | 57 | 62.00 ± 7.16 | 58.20 (49.44−74.35) | 0.08 b | 0.14 |
| CpG site 4 | 44 | 59.08 ± 5.04 | 62.30 (50.52−64.39) | 57 | 59.17 ± 4.38 | 61.24 (48.66−64.35) | 0.34 b | 0.42 |
| CpG site 5 | 44 | 66.18 ± 2.41 | 66.47 (57.53−72.28) | 57 | 67.26 ± 1.11 | 67.14 (63.51−70.59) | 0.005 b,* | 0.02 * |
| All CpG sites combined | 44 | 68.04 ± 1.55 | 68.63 (64.98−70.37) | 57 | 66.83 ± 2.33 | 65.93 (62.48−72.48) | 0.005 b,* | |
N varied based on the success of pyrosequencing assay. a t-tests. b Mann-Whitney tests. c False Discovery Rate. * Statistically significant.